

Advanced Health Intelligence Ltd Appointment of new Chief Executive Officer

Appointment Highlights

- Mr Dylan Garnett has been appointed as the new CEO of AHI and brings over 25 years of executive leadership across healthcare, insurance, and technology, with a track record of growing businesses and delivering business outcomes.
- Co-founder of Vertica Health (acquired by AHI in 2022), and instrumental in driving AHI's product innovation and market expansion as Chief Innovation Officer.
- Former CEO/MD of Metropolitan Health, one of South Africa's largest health administrators, overseeing millions of insured lives and multi-billion-dollar premiums and claims operations.
- Experience in digital health and computational physiology as COO/CCO of LifeQ, where he helped commercialise and operationalise advanced health modelling technologies now powering leading global wearable and health platforms.
- Appointment aligns with AHI's strategic shift toward commercialisation and revenue growth, reinforcing the Company's focus on stronger execution, shareholder value creation, and long-term sustainability.

South Perth, 16 September 2025 – Advanced Health Intelligence Ltd (“**AHI**” or “**the Company**”) is pleased to announce the appointment of Mr Dylan Garnett as Chief Executive Officer, effective immediately.

Mr Garnett brings more than two decades of executive leadership across healthcare, insurance, and technology, with proven expertise in leading businesses, driving commercialisation, and building partnerships. He joined AHI in 2022 following the acquisition of Vertica Health, where he was co-founder and CEO, and has since served as AHI's Chief Innovation Officer, driving product development and market expansion in digital health.

Prior to AHI, Mr Garnett held senior leadership roles, including Chief Executive Officer and Managing Director at Metropolitan Health, one of South Africa's largest health administrators, responsible for managing millions of insured lives and multi-billion-dollar premiums and claims administration.

He was also COO/CCO at LifeQ, a global pioneer in computational physiology and biometric sensor data, where he helped transition and restructure the business for growth. LifeQ is widely recognised for developing sophisticated physiological models that power wearable devices and digital health platforms across the world. Its technology underpins partnerships with leading global brands in consumer electronics, healthcare, and insurance, enabling real-time monitoring of cardiovascular, metabolic, and respiratory health at scale.

During his tenure, Mr Garnett was instrumental in shaping LifeQ's business strategy and building out its operations, bridging the gap between advanced science and real-world applications. This experience directly complements AHI's technology stack, which also focuses on extracting validated health insights from user-captured data and delivering them into healthcare, insurance, and corporate wellness ecosystems.

By bringing this expertise into AHI, Mr Garnett strengthens the Company's ability to accelerate commercial adoption of its proprietary health assessment tools, while ensuring scientific credibility and alignment with international digital health standards.

For personal use only

He also previously held executive roles with Zurich Insurance, one of the world's leading global insurers, where he gained direct exposure to risk modelling, product design, and customer engagement strategies across health and life insurance portfolios. This experience directly aligns with AHI's mission of applying validated digital health insights to improve underwriting accuracy, enhance customer engagement, and support value-based models in insurance.

His academic background includes postgraduate qualifications in Clinical Psychology and Marketing, supplemented with executive leadership programmes, providing both the scientific and commercial grounding to lead AHI through its next phase of growth.

Background – Mr Dylan R. Garnett

- 25+ years' leadership across healthcare, insurance, and technology; extensive global partnership network.
- Co-founder of Vertica Health (acquired by AHI in 2022).
- Former CEO/MD, Metropolitan Health – one of South Africa's largest health administrators, managing millions of insured lives.
- Former COO/CCO, LifeQ, with expertise in digital health and data science applications.
- Experienced in venture building, product/market fit, commercial scaling, and investor engagement.

Mr Garnett's appointment comes at a pivotal time for AHI. The Company is executing several strategic changes as it progresses through its ASX reinstatement process and positions itself for its next phase of growth. The Board is focused on streamlining operations, reducing costs, and realigning the Company around commercial execution and revenue growth.

With his extensive track record in health technology, corporate partnerships, and scaling revenue-generating businesses, Mr Garnett is ideally placed to lead this transition. The Board believes his appointment signals a clear commitment to stronger commercial outcomes, deeper market penetration, and enhanced value creation for shareholders as AHI moves into its next chapter.

Remuneration & Material Terms

Mr Garnett will receive a fixed base salary of US\$240,000 per annum, which reflects market benchmarks for executives of ASX-listed technology and digital health companies of comparable size and stage.

In addition to his base salary, the Company is finalising a performance securities package for Mr Garnett, designed to align his long-term incentives directly with shareholder value creation. The package is intended to mirror the structure applied to the previous CEO role, ensuring that Mr Garnett is rewarded only in line with the Company's success - tied explicitly to revenue growth, share price performance, and achievement of commercial outcomes. Details of this equity-based package will be provided in a market update in the coming weeks once finalised.

The material terms of Mr Garnett's engagement are consistent with market practice for an ASX-listed company and include provisions covering:

- **Notice Period and Termination:** Both the Company and the Executive may terminate the agreement by providing three (3) months' notice without cause, or one (1) month's notice where termination is for cause.(both Company and executive);
- **Short-term incentive eligibility** (performance-linked milestones tied to operational and financial delivery);
- **Participation in the Company's Employee Securities Incentive Plan**, subject to shareholder approval where required;
- **Confidentiality and intellectual property protection** obligations;
- **Restraint of trade / non-competition undertakings** for a defined period post-engagement; and
- **Entitlement to standard executive benefits**, including annual and personal leave in line with statutory requirements.

A full summary of the final material terms will be disclosed in accordance with the applicable ASX Listing Rules upon finalisation of Mr Garnett's performance securities package.

Mr Garnett's incentives are fully aligned with shareholder outcomes, reinforcing long-term value creation.

Mr Garnett replaces outgoing CEO Mr Scott Montgomery, who has also resigned as an Executive Director. AHI wishes to thank Mr Montgomery for his contribution to the Company during his tenure.

Statement from Vlado Bosanac, Founder and Head of Strategy at AHI

"It has been a privilege working alongside Dylan Garnett for the past three years. During this time, he has consistently demonstrated the commercial insight, discipline, and leadership capabilities that have already delivered measurable value to AHI. His expertise across healthcare, insurance, and technology has been instrumental in advancing our product development and commercial partnerships, positioning the Company strongly for its next phase of growth.

The Board considers Dylan's appointment a critical and timely evolution of our leadership team as AHI transitions into a period of deeper commercialisation and revenue generation. His proven ability to align strategic vision with execution provides the Company with the leadership required to accelerate its pathway to sustainable growth and enhanced shareholder value."

The Chairman of Advanced Health Intelligence Ltd has approved this release.

For more information, contact:

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Limited
E: admin@ahi.tech

Simon Durack
Company Secretary & CFO
Advanced Health Intelligence Limited
E: admin@ahi.tech

For more information, please visit: www.ahi.tech

About Advanced Health Intelligence Ltd

AHI offers cutting-edge, smartphone-based health risk identification solutions that enable individuals to run their own comprehensive health assessments and risk stratification.

Utilising smartphone sensor technology, individuals can efficiently conduct a single scan or a series of scans to identify established risk markers for various health conditions. The resulting data can then be shared with healthcare providers, insurers, employers, and government agencies, facilitating timely triage and the allocation of appropriate care pathways.

AHI's scientific research capability is dedicated to the development of advanced data capture techniques, optimising data input signal quality and continuous enhancement and validation of AHI's solutions through rigorous scientific processes. AHI has assembled a team of experts in machine learning, artificial intelligence, biomathematical modelling and systems biology, computer vision, clinical expertise, and medically trained data scientists to develop and deploy these cutting-edge risk assessment tools.

Over the past decade, AHI has been at the forefront of health-tech innovation, pioneering the use of smartphones in digital-first health care. Our journey began with the groundbreaking development of the world's first on-device body dimensioning capability.

Since then, we have continued to evolve and adapt our solutions to meet the dynamic needs of health systems players dedicated to delivering high-quality patient care and early detection of escalating health conditions.

AHI's patented technology has enabled us to push the boundaries of early detection through digital health care, offering a suite of modular solutions that are transforming the industry and offering earlier intervention opportunities.

Our comprehensive solutions encompass:

- Anthropometric and body composition analysis to identify obesity-related comorbidities, including diabetes risk stratification.
- Predictive modelling of blood biomarkers (including HbA1C, HDL-C, LDL-C), and 10-year cardiovascular risk estimation.
- Facial photoplethysmography to assess vital signs non-invasively and provide risk stratification for cardiovascular disease.
- Device-derived dermatological image analysis for identifying over 588 skin conditions across 134 categories, including melanoma detection.
- Atrial Fibrillation technology enables the detection of Atrial Fibrillation using a mobile device. This allows for early identification and monitoring of this common heart condition through a simple, non-invasive, and user-friendly smartphone-based solution.

AHI has developed digital biomarker-driven triage solutions that use only a smartphone or web browser. These solutions enable the identification of health risks across populations and can inform the direction of individuals to appropriate care pathways for proactive health management. The technology provides cost-effective health risk assessment access to billions of smartphone users worldwide, empowering these individuals to take charge of their health journey and improving health outcomes globally.